CD30, an activation-induced antigen expressed in subsets of normal T-cells and B-cells, is expressed in DLBCL approx. 30% of the time and is another potential therapeutic target [69]. The gene discussed is TNFRSF8; the disease is diffuse large B-cell lymphoma.